Literature DB >> 20345213

An overview about hepatitis C: a devastating virus.

Nazish Bostan1, Tariq Mahmood.   

Abstract

Hepatitis C (HCV) is the disease that has affected around 200 million people globally. HCV is a life threatening human pathogen, not only because of its high prevalence and worldwide burden but also because of the potentially serious complications of persistent HCV infection. Chronicity of the disease leads to cirrhosis, hepatocellular carcinoma and end-stage liver disease. HCV positive hepatocytes vary between less than 5% and up to 100%, indicating the high rate of replication of viral RNA. HCV has a very high mutational rate that enables it to escape the immune system. Viral diversity has two levels; the genotypes and Quasiaspecies. Major HCV genotypes constitute genotype 1, 2, 3, 4, 5 and 6 while more than 50 subtypes are known. All HCV genotypes have their particular patterns of geographical distribution and a slight drift in viral population has been observed in some parts of the globe.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345213     DOI: 10.3109/10408410903357455

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  31 in total

1.  EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Authors:  Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus.

Authors:  Hong Zhao; Wenyu Lin; Kattareeya Kumthip; Du Cheng; Dahlene N Fusco; Oliver Hofmann; Nikolaus Jilg; Andrew W Tai; Kaku Goto; Leiliang Zhang; Winston Hide; Jae Young Jang; Lee F Peng; Raymond T Chung
Journal:  J Hepatol       Date:  2011-08-31       Impact factor: 25.083

3.  Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation?

Authors:  Mónica Viviana Alvarado-Mora; María Fernanda Gutierrez Fernandez; Michele Soares Gomes-Gouvêa; Raymundo Soares de Azevedo Neto; Flair José Carrilho; João Renato Rebello Pinho
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

4.  SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication.

Authors:  Run-Xuan Shao; Leiliang Zhang; Zhi Hong; Kaku Goto; Du Cheng; Wen-Chi Chen; Nikolaus Jilg; Kattareeya Kumthip; Dahlene N Fusco; Lee F Peng; Raymond T Chung
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

5.  IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-κB pathway.

Authors:  Cynthia Brisac; Shadi Salloum; Victor Yang; Esperance A K Schaefer; Jacinta A Holmes; Stephane Chevaliez; Jian Hong; Charlie Carlton-Smith; Nadia Alatrakchi; Annie Kruger; Wenyu Lin; Raymond T Chung
Journal:  J Hepatol       Date:  2016-07-09       Impact factor: 25.083

6.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 7.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

Authors:  Katherine A McGlynn; Jessica L Petrick; W Thomas London
Journal:  Clin Liver Dis       Date:  2015-02-26       Impact factor: 6.126

8.  ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using 64Cu-labeled daratumumab.

Authors:  Shiyong Li; Christopher G England; Emily B Ehlerding; Christopher J Kutyreff; Jonathan W Engle; Dawei Jiang; Weibo Cai
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

9.  Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study.

Authors:  Ghada Abdelmoemen; Samy Abdelkader Khodeir; Sabry Abou-Saif; Abdelrahman Kobtan; Sherief Abd-Elsalam
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-06       Impact factor: 4.223

10.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.